STOCK TITAN

Phenomex - CELL STOCK NEWS

Welcome to our dedicated page for Phenomex news (Ticker: CELL), a resource for investors and traders seeking the latest updates and insights on Phenomex stock.

PhenomeX Inc. (Nasdaq: CELL) delivers essential updates for stakeholders tracking innovations in functional cell biology and biopharma research. This comprehensive resource aggregates official announcements, financial disclosures, and strategic developments from the leader in single-cell manipulation technologies.

Access timely updates on PhenomeX's industry-leading platforms including the Beacon system for antibody discovery and IsoSpark™ proteomics solutions. The page features critical business developments such as pending acquisition activity, quarterly financial performance, and new product launches like the Opto® Memory B Discovery workflow.

Key content categories include earnings reports, partnership announcements with global pharmaceutical leaders, intellectual property updates, and operational expansions. Investors will find maintained revenue guidance analysis while researchers discover technical specifications for cutting-edge tools accelerating therapeutic development.

Bookmark this page for structured access to PhenomeX's verified corporate communications. Check regularly for updates on strategic initiatives shaping the future of precision cell biology and diagnostic innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
Rhea-AI Summary
PhenomeX to showcase optofluidic and proteomic technologies at PEGS Conference and Expo
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.39%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

On April 17, 2023, PhenomeX (Nasdaq: CELL) unveiled its new Opto® T Cell Profiling workflow, designed to enhance the characterization of T cells for immunotherapy development. This innovative technology allows for the comprehensive profiling of single T cells, linking their polyfunctionality with cytotoxicity, which is crucial for identifying potent anti-tumor agents. The Optofluidic Platforms utilize opto-electropositioning to isolate T cells in NanoPen chambers, facilitating advanced assays that enable researchers to correlate cytokine secretion and gene sequences. The company showcased these advancements at the AACR Annual Meeting 2023 in Orlando, Florida, highlighting their commitment to revolutionizing cancer research. The new workflow promises to empower scientists with deeper insights into cell function, significantly impacting the future of immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
Rhea-AI Summary

PhenomeX (Nasdaq: CELL) announced the appointment of Peter Silvester to its board of directors, effective immediately. Silvester, who has over 25 years of experience in the life sciences industry, previously served as senior vice president and president of Life Sciences Solutions for Thermo Fisher Scientific. His expertise spans critical areas such as mergers and acquisitions, commercial operations, and finance.

CEO Siddhartha Kadia emphasized that Silvester's extensive knowledge and insights will be pivotal as PhenomeX seeks to lead in functional cell biology. Silvester will sit on the Audit and Compensation & Leadership Development Committees. His addition comes at a significant time for PhenomeX, which aims to empower scientists and enhance disease treatment through innovative solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.93%
Tags
management
-
Rhea-AI Summary

PhenomeX Inc. (Nasdaq: CELL) announced its participation in the AACR Annual Meeting 2023 from April 14-19 in Orlando, Florida. The conference focuses on advancements in cancer science and medicine, highlighting the theme "Advancing the Frontiers of Cancer Science and Medicine." PhenomeX, formed from the merger of Isoplexis and Berkeley Lights (Nasdaq: BLI), will showcase its IsoSpark and Beacon® optofluidic platform technologies at booth #3444. Attendees can see demonstrations and learn about applications that provide insights into cell function relevant to scientific discovery, bioprocessing, and clinical research. Additionally, PhenomeX technologies will feature in nine poster presentations covering various cancer research topics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

PhenomeX (Nasdaq: CELL) has appointed Dr. Yan Zhang as Chief Commercial Officer, effective immediately, to enhance its global commercial strategy. Dr. Zhang, with nearly 25 years in the life sciences industry and experience from Mission Bio and Thermo Fisher Scientific, will lead the expanded commercial organization following the merger of Berkeley Lights and IsoPlexis. Additionally, Tomoya Aoyama will manage commercial operations in the APAC region. Both leaders are expected to drive strategic growth and strengthen the company's market presence in a key growth area. This leadership change aligns with PhenomeX’s goal of advancing cell biology and therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
management
Rhea-AI Summary

Berkeley Lights, Inc. has completed its acquisition of IsoPlexis Corporation, leading to the formation of PhenomeX. Trading under the ticker CELL, this newly merged entity aims to be a leader in life sciences solutions. The merger is expected to deliver $70 million in cost synergies and boost profitability as it targets a growing market for functional cell biology. In 2022, the combined revenue was approximately $95 million, with a significant installed base of instruments in major pharmaceutical companies and cancer centers. Share distribution post-merger shows Berkeley Lights shareholders owning roughly 75.2% of PhenomeX.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
Phenomex

Nasdaq:CELL

CELL Rankings

CELL Stock Data

98.79M
87.41M
11.82%
55.85%
1.3%
Biotechnology
Healthcare
Link
United States
EmeryVille